Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT07029295Not yet recruiting
Randomised, open-label trial (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Success rate of suppression of residual myocardial FDG uptake. Planned start Jul 2025; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT07029295.